

## DAFTAR PUSTAKA

1. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Cancer today.
2. Putriani FA, Kholis FN, Purwoko Y. Perbedaan Faktor Risiko Penderita Adenokarsinoma Paru dengan Mutasi EGFR dan Non Mutasi EGFR. 2019;8(1):8.
3. Sari L, Purwanto P. Mutasi EGFR pada Non-Small Cell Lung Cancer di Rumah Sakit Kanker “Dharmais.” *Indones J Cancer*. 2017 Sep 19;10(4):131.
4. Ahmad AS, Mayya AM. A new tool to predict lung cancer based on risk factors. *Heliyon*. 2020;6(2).
5. Rosai J, Ackerman LV. *Surgical pathology*. Edinburgh; New York: Mosby; 2011.
6. The Lung Cancer Project [Internet]. Available from: <https://www.thelungcancerproject.org/>
7. Bethune G, Bethune D, Ridgway N, Xu Z. Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. *J Thorac Dis*. 2010 Mar;2(1):48–51.
8. Herbst RS. Review of epidermal growth factor receptor biology. *Int J Radiat Oncol*. 2004 Jun;59(2):S21–6.
9. Putra AC, Nurwidya F, Andarini S, Zaini J, Syahrudin E, Hudoyo A, et al. Masalah Kanker Paru pada Lanjut Usia. 2015;42(11):5.
10. Lavacchi D, Mazzone F, Giaccone G. Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives. *Drug Des Devel Ther*. 2019 Sep;Volume 13:3187–98.
11. Pallis AG, Syrigos KN. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC. *Lung Cancer*. 2013 May;80(2):120–30.
12. Sherwood L. *Human physiology: from cells to systems*. 9th edition. Boston, MA, USA: Cengage Learning; 2016. 1 p.
13. Junqueira LCU, Mescher AL, editors. *Junqueira’s basic histology: text & atlas*. 12. ed. New York: McGraw-Hill Medical; 2010. 467 p.

14. Ball M, Hossain M, Padalia D. Anatomy, Airway. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 [cited 2020 Jul 16]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK459258/>
15. Human anatomy, color atlas and textbook + student consult online access. Place of publication not identified: Elsevier; 2016.
16. Moore KL, Dalley AF, Agur AMR. Clinically oriented anatomy. 7th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins Health; 2014. 1134 p.
17. Singapore Cancer Society. Lung Cancer. 2017.
18. Houston KA, Mitchell KA, King J, White A, Ryan BM. Histologic Lung Cancer Incidence Rates and Trends Vary by Race/Ethnicity and Residential County. *J Thorac Oncol*. 2018 Apr;13(4):497–509.
19. Dela Cruz CS, Tanoue LT, Matthay RA. Lung Cancer: Epidemiology, Etiology, and Prevention. *Clin Chest Med*. 2011 Dec;32(4):605–44.
20. Steiling K, Campbell JD. Genetics of Lung Cancer. In: Gomez JL, Himes BE, Kaminski N, editors. *Precision in Pulmonary, Critical Care, and Sleep Medicine*. Cham: Springer International Publishing; 2020. p. 87–103. (Respiratory Medicine).
21. Mustafa M, Azizi ARJ, Illzam El, Nazirah A, Sharifa S, Abbas Sa. Lung Cancer: Risk Factors, Management, And Prognosis. *IOSR J Dent Med Sci*. 2016 Oct;15(10):94–101.
22. Bade BC, Dela Cruz CS. Lung Cancer 2020. *Clin Chest Med*. 2020 Mar;41(1):1–24.
23. Kementerian Kesehatan Republik Indonesia. *Pedoman Nasional Pelayanan Kedokteran Kanker Paru*. Jakarta: Kementerian Kesehatan Republik Indonesia; 2017.
24. MacRosty CR, Rivera MP. Lung Cancer in Women. *Clin Chest Med*. 2020 Mar;41(1):53–65.
25. Weinberger SE, Cockrill BA, Mandel J. *Principles of pulmonary medicine*. Seventh edition. Philadelphia, PA: Elsevier; 2019.
26. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2018 Nov;68(6):394–424.

27. Toh C-K, Gao F, Lim W-T, Leong S-S, Fong K-W, Yap S-P, et al. Never-Smokers With Lung Cancer: Epidemiologic Evidence of a Distinct Disease Entity. *J Clin Oncol*. 24(15):2245–51.
28. Greillier L, Morere J-F, Viguier J, Touboul C, Blay J-Y, Eisinger F, et al. Awareness of Lung Cancer Risk Factors among Lay Persons and Physicians. *J Thorac Oncol*. 2017 Jan;12(1):S453–4.
29. Torres-Duran M, Fernandez-Villar A, Barros-Dios JM, Ruano-Ravina A. Residential Radon: The Neglected Risk Factor in Lung Cancer Risk Scores. *J Thorac Oncol*. 2016 Sep;11(9):1384–6.
30. Macedo-Perez O, Gonzalez IL, Bornstein L, Castellanos J, Campos-Peralta K, Jimenez-Fuentes E. Environmental Pollution in the City of Mexico as a Risk Factor for Lung Cancer and Its Prognostic Impact. *J Thorac Oncol*. 2019 Oct;14(10):S788.
31. Kristina SA, Endarti D, Sendjaya N, Pramestuty O. Estimating the Burden of Cancers Attributable to Smoking Using Disability Adjusted Life Years in Indonesia. *Asian Pac J Cancer Prev*. 2016 Apr 11;17(3):1577–81.
32. Sholih MG, Perwitasari DA, Hendriani R, Sukandar H, Barliana I, Suwantika A, et al. Risk factors of Lung Cancer in Indonesia: a qualitative study. 2019;9(2):5.
33. Myers DJ, Wallen JM. Cancer, Lung Adenocarcinoma. In: *StatPearls*. Treasure Island (FL): StatPearls Publishing; 2020.
34. Gridelli C, Rossi A, Carbone DP, Guarize J, Karachaliou N, Mok T, et al. Non small cell lung cancer. *Nat Rev Dis Primer*. 2015 Dec;1(1):15009.
35. Travis WD, Brambilla E, Burke A, Marx A, Nicholson A. WHO classification of tumours of lung, pleura, thymus and heart. 4th ed. Lyon; 2015. 11 p.
36. Gazdar AF. Molecular pathogenesis of lung cancer and its precursor lesions. *J Thorac Oncol*. 2007 Aug;2(8):S191–2.
37. Roskoski R. The ErbB/HER family of protein-tyrosine kinases and cancer. *Pharmacol Res*. 2014 Jan;79:34–74.
38. Zhanhua C, Gan JG-K, lei L, Sakharkar MK, Kanguane P. Protein subunit interfaces: heterodimers versus homodimers. *Bioinformation*. 2005 Aug 11;1(2):28–39.

39. Baraibar I, Mezquita L, Gil-Bazo I, Planchard D. Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC. *Crit Rev Oncol Hematol*. 2020 Apr;148:102906.
40. Xu X-W, Weng X-H, Wang C-L, Lin W-W, Liu A-L, Chen W, et al. Detection EGFR exon 19 status of lung cancer patients by DNA electrochemical biosensor. *Biosens Bioelectron*. 2016 Jun;80:411–7.
41. Chan BA, Hughes BGM. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. *Transl Lung Cancer Res*. 2015;4(1):19.
42. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers. *JNCI J Natl Cancer Inst*. 2005 Mar 2;97(5):339–46.
43. Rima A, Mayasari H, Sunarso S, Sutanto Y. The Correlation Between One Year Survival and the Affecting Factors of Lung Cancer Patients at Dr. Moewardi Hospital Surakarta. *J Thorac Oncol*. 2017 Nov;12(11):S2086.
44. Schuler M, Wu Y-L, Hirsh V, O’Byrne K, Yamamoto N, Mok T, et al. First-Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases. *J Thorac Oncol*. 2016 Mar;11(3):380–90.
45. Goebel C, Loudon CL, Mckenna R, Onugha O, Wachtel A, Long T. Diagnosis of Non-small Cell Lung Cancer for Early Stage Asymptomatic Patients. *Cancer Genomics - Proteomics*. 2019;16(4):229–44.
46. Veluswamy R, Gomez JE. Lung Cancer. In: Oh W, Chari A, editors. *Mount Sinai Expert Guides*. 1st ed. Wiley; 2019. p. 66–78.
47. Kementerian Kesehatan Republik Indonesia. *Pedoman Nasional Pelayanan Kedokteran Kanker Paru*. Jakarta: Kementerian Kesehatan Republik Indonesia; 2017.
48. Xu S-T, Xi J-J, Zhong W-Z, Mao W-M, Wu L, Shen Y, et al. The Unique Spatial Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial. *J Thorac Oncol*. 2019 Mar;14(3):503–12.
49. Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors. *J Thorac Oncol*. 2018 Mar;13(3):323–58.

50. Baskar R, Lee KA, Yeo R, Yeoh K-W. Cancer and Radiation Therapy: Current Advances and Future Directions. *Int J Med Sci.* 2012;9(3):193–9.
51. Sridhar T, Symonds RP. Principles of chemotherapy and radiotherapy. *Obstet Gynaecol Reprod Med.* 2009 Mar;19(3):61–7.
52. Khalifa J, Amini A, Popat S, Gaspar LE, Faivre-Finn C. Brain Metastases from NSCLC: Radiation Therapy in the Era of Targeted Therapies. *J Thorac Oncol.* 2016 Oct;11(10):1627–43.
53. Di Lalla V, Chaput G, Williams T, Sultanem K. Radiotherapy side effects: integrating survivorship clinical lens to better serve patients. *Curr Oncol.* 2019 Dec 16;27(2).
54. Hellmann MD, Li BT, Chaft JE, Kris MG. Chemotherapy remains an essential element of personalized care for persons with lung cancers. *Ann Oncol.* 2016 Oct;27(10):1829–35.
55. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of Four Chemotherapy Regimens for Advanced Non-Small-Cell Lung Cancer. *N Engl J Med.* 2002 Jan 10;346(2):92–8.
56. Pirker R. Chemotherapy remains a cornerstone in the treatment of nonsmall cell lung cancer: *Curr Opin Oncol.* 2020 Jan;32(1):63–7.
57. Thomas A, Rajan A, Giaccone G. Tyrosine Kinase Inhibitors in Lung Cancer. *Hematol Oncol Clin North Am.* 2012 Jun;26(3):589–605.
58. Sculier J-P, Berghmans T, Meert A-P. Advances in target therapy in lung cancer. *Eur Respir Rev.* 2015 Mar;24(135):23–9.
59. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. *Lancet Oncol.* 2012 Mar;13(3):239–46.
60. Mok TSK. Mirror Mirror on the Wall, Who Is the Fairest of Them All. *J Thorac Oncol.* 2014 Apr;9(4):431–2.
61. Shih Y-N, Liou J-L, Jiang W-C, Chang K-T, Chiu C-H, Tsai C-M. Phase II study of erlotinib in patients with advanced non-small cell lung cancer who failed prior gefitinib treatment. *J Thorac Oncol.* 2007 Aug;2(8):S743.

62. Omori S, Oyakawa T, Naito T, Takahashi T. Gefitinib Induced Cardiomyopathy in Epidermal Growth Receptor Mutated NSCLC. *J Thorac Oncol*. 2018 Oct;13(10):e207–8.
63. Russo A, Franchina T, Ricciardi GRR, Smiroldo V, Picciotto M, Zanghì M, et al. Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going. *Crit Rev Oncol Hematol*. 2017 Sep;117:38–47.
64. Horn L, Gettinger S, Camidge DR, Smit EF, Janjigian YY, Miller VA, et al. Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. *Lung Cancer*. 2017 Nov;113:51–8.
65. Peters S, Curioni-Fontecedro A, Nechushtan H, Shih J-Y, Liao W-Y, Gautschi O, et al. Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program. *J Thorac Oncol*. 2018 Dec;13(12):1897–905.
66. Yang Z, Hackshaw A, Feng Q, Fu X, Zhang Y, Mao C, et al. Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis. *Int J Cancer*. 2017 Jun 15;140(12):2805–19.
67. Soria J-C, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, et al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. *Lancet Oncol*. 2015 Aug;16(8):897–907.
68. Shirley M. Dacomitinib: First Global Approval. *Drugs*. 2018 Dec;78(18):1947–53.
69. Wecker H, Waller CF. Afatinib. In: Martens UM, editor. *Small Molecules in Oncology*. Cham: Springer International Publishing; 2018. p. 199–215. (Recent Results in Cancer Research; vol. 211).
70. Wu S-G, Liu Y-N, Tsai M-F, Chang Y-L, Yu C-J, Yang P-C, et al. The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients. *Oncotarget*. 2016 Mar 15;7(11):12404–13.
71. Lazzari C, Gregorc V, Karachaliou N, Rosell R, Santarpia M. Mechanisms of resistance to osimertinib. *J Thorac Dis*. 2020 May;12(5):2851–8.
72. Mazzarella L, Guida A, Curigliano G. Cetuximab for treating non-small cell lung cancer. *Expert Opin Biol Ther*. 2018 Apr 3;18(4):483–93.

73. Hasegawa H, Yasuda H, Hamamoto J, Masuzawa K, Tani T, Nukaga S, et al. Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations. *Lung Cancer*. 2019 Jan;127:146–52.
74. Chen Y-F, Hsieh M-S, Wu S-G, Chang Y-L, Yu C-J, Yang JC-H, et al. Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations. *J Thorac Oncol*. 2016 Jul;11(7):1140–52.
75. Yang JC-H, Cheng Y, Murakami H, Yang P-C, He J, Nakagawa K, et al. A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis. *J Thorac Oncol*. 2020 Jan;15(1):91–100.
76. Tan DS-W, Araújo A, Zhang J, Signorovitch J, Zhou Z-Y, Cai X, et al. Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK-Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls. *J Thorac Oncol*. 2016 Sep;11(9):1550–7.
77. Camidge DR, Kim EE, Usari T, Polli A, Lewis I, Wilner KD. Renal Effects of Crizotinib in Patients With ALK-Positive Advanced NSCLC. *J Thorac Oncol*. 2019 Jun;14(6):1077–85.
78. Wu Y-L, Lu S, Lu Y, Zhou J, Shi Y, Sriuranpong V, et al. Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer. *J Thorac Oncol*. 2018 Oct;13(10):1539–48.
79. Dorrans B, Llano A. Bevacizumab. *Pract Diabetes*. 2020 Mar;37(2):70–1.